A new drug has been found to nearly double survival rates in some pancreatic cancer patients, with the benefit seen in those with advanced forms of the disease. The drug, referred to as daraxonrasib in some reports, has shown promising results in a landmark study. The exact nature and extent of the drug's effectiveness are still being reported, with some outlets noting its potential to change treatment approaches for one of the deadliest forms of cancer.